Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CAM2043
- Development stage
- Unknown
- Lead developer
- Camurus
- Modality
- Small Molecules
- Administration
- Subcutaneous
01
Overview
CAM2043 is an investigational long-acting subcutaneous depot formulation of treprostinil, developed by Camurus using its proprietary FluidCrystal® technology. Treprostinil is a small molecule prostacyclin (IP) receptor agonist that induces vasodilation and inhibits platelet aggregation and smooth muscle cell proliferation. CAM2043 is designed for once-weekly self-administration to provide continuous therapeutic levels of treprostinil, aiming to improve upon existing continuous infusion systems that are often associated with site pain and infection risks. It is currently being evaluated for the treatment of pulmonary arterial hypertension (PAH) and Raynaud's phenomenon secondary to systemic sclerosis.
- Other names
- treprostinil subcutaneous depotFluidCrystal treprostinil
02
Targets
Beyond the preview
Go deeper on CAM2043.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CAM2043.